Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 21/11/2017
SIETES contiene 92130 citas

 
 
 1 a 20 de 348 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
2. Cita con resumen
Woloshin S, Schwartz LM, White B, Moore TJ. The fate of FDA postapproval studies. N Engl J Med 2017;377:1114-7. [Ref.ID 102072]
5.Enlace a cita original Cita con resumen
Prasad V, Mailan S. Research and development spending to bring a single cancer drug to market and revenues after approval. JAMA Intern Med 2017;177:1569-75. [Ref.ID 102051]
6. Cita con resumen
Anónimo. FDA Approves CAR-T therapy for treatment of childhood leukemia. DIA Daily 2017:1. [Ref.ID 102036]
7.Tiene citas relacionadas Cita con resumen
Eunjung Cha A. Monthly shot could be the ‘next revolution’ in HIV therapy, replacing daily pills. The Washington Post 2017:1. [Ref.ID 101921]
8.Enlace a cita originalTiene citas relacionadas Cita con resumen
Feuerstein A. STAT Plus: Strong results for a new HIV drug will be a big boost to Gilead Sciences. STAT 2017:24 de julio. [Ref.ID 101919]
9.Enlace a cita original Cita con resumen
Bouvy JC, Blake K, Slattery J, De Bruin ML, Arlett P, Kurz X. Registries in European post-marketing surveillance: a retrospective analysis of centrally approved products, 2005–2013. Pharmacoepidemiol Drug Saf 2017:26 de marzo. [Ref.ID 101903]
10. Cita con resumen
Huang Z, Ma J. Chronic purulent nasal discharge. BMJ 2017;357:j2061. [Ref.ID 101636]
11. Cita con resumen
Al-Khateeb Z, Hadker N, Scaife JG, Miyasato G, Sanchez H. What we value: the proposition behind the price. Trinity Partners 2017:26 de mayo. [Ref.ID 101602]
12. Cita con resumen
Pease AM, Krumholz HM, Hines HH, Downing NS, Aminawung JA, Shah ND, Ross JS. Postapproval studies of drugs initially approved by the FDA on the basis of limited evidence: systematic review. BMJ 2017;357:j1680. [Ref.ID 101573]
13. Cita con resumen
Downing NS, Shah ND, Aminawung JA, Pease AM, Zeitoun JD, Krumholz HM, Ross JS. Postmarket safety events among novel therapeutics approved by the US Food and Drug Administration between 2001 and 2010. JAMA 2017;317:1854-63. [Ref.ID 101567]
14. Cita con resumen
Anónimo. FDA pushes back on Trump’s claims of slow drug reviews. DIA Daily 2017:8. [Ref.ID 101452]
16. Cita con resumen
Khan AR, Bavishi C, Riaz H, Farid TA, Khan S, Atlas M, Hirsch G, Ikram S, Bolli R. Increased risk of adverse neurocognitive outcomes with proprotein convertase subtilisin-kexin type 9 inhibitors. Circulation: Cardiovascular Quality and Outcomes 2017;10:e003153. [Ref.ID 101377]
17. Cita con resumen
Anónimo. FDA approves fewest new drugs last year since 2010. DIA Daily 2017:2. [Ref.ID 101018]
18.Enlace a cita original
Pfeffer MA, McMurray JJV. Lessons in uncertainty and humility — Clinical trials involving hypertension. N Engl J Med 2016;375:1756-66. [Ref.ID 100966]
19. Cita con resumen
Novoa A. Medicina personalizada: mitos, ciencia “low cost” e intereses. NoGracias 2016:1. [Ref.ID 100860]
20. Cita con resumen
Anónimo. FDA grants breakthrough status to tocilizumab for giant cell arteritis. DIA Daily 2016:5. [Ref.ID 100784]
Seleccionar todas
 
 1 a 20 de 348 siguiente >>